


List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5525061/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation. Journal of Cellular and Molecular Medicine, 2021, 25, 1568-1582.	3.6	21
2	Myofibroblast‧pecific Msi2 Knockout Inhibits HCC Progression in a Mouse Model. Hepatology, 2021, 74, 458-473.	7.3	15
3	EFTUD2 maintains the survival of tumor cells and promotes hepatocellular carcinoma progression via the activation of STAT3. Cell Death and Disease, 2020, 11, 830.	6.3	17
4	The Effects of Chloroquine and Hydroxychloroquine on ACE2-Related Coronavirus Pathology and the Cardiovascular System: An Evidence-Based Review. Function, 2020, 1, .	2.3	12
5	Pyruvate Kinase M2 Tetramerization Protects against Hepatic Stellate Cell Activation and LiverÂFibrosis. American Journal of Pathology, 2020, 190, 2267-2281.	3.8	32
6	Intrahepatic cholangiocarcinoma induced M2-polarized tumor-associated macrophages facilitate tumor growth and invasiveness. Cancer Cell International, 2020, 20, 586.	4.1	30
7	Dexmedetomidine promotes the progression of hepatocellular carcinoma through hepatic stellate cell activation. Experimental and Molecular Medicine, 2020, 52, 1062-1074.	7.7	29
8	Expression of hepatic stellate cell activation-related genes in HBV-, HCV-, and nonalcoholic fatty liver disease-associated fibrosis. PLoS ONE, 2020, 15, e0233702.	2.5	19
9	RCE1 deficiency enhances invasion via the promotion of epithelial-mesenchymal transition and predicts poor prognosis in hepatocellular carcinoma. American Journal of Translational Research (discontinued), 2020, 12, 7236-7248.	0.0	1
10	Tyrosine kinase SYK is a potential therapeutic target for liver fibrosis. Hepatology, 2018, 68, 1125-1139.	7.3	74
11	<scp>RPA</scp> 3 is a potential marker of prognosis and radioresistance for nasopharyngeal carcinoma. Journal of Cellular and Molecular Medicine, 2017, 21, 2872-2883.	3.6	38
12	An inflammatory biomarkerâ€based nomogram to predict prognosis of patients with nasopharyngeal carcinoma: an analysis of a prospective study. Cancer Medicine, 2017, 6, 310-319.	2.8	80
13	RBM24 suppresses cancer progression by upregulating miR-25 to target MALAT1 in nasopharyngeal carcinoma. Cell Death and Disease, 2016, 7, e2352-e2352.	6.3	58
14	BRCC3 acts as a prognostic marker in nasopharyngeal carcinoma patients treated with radiotherapy and mediates radiation resistance in vitro. Radiation Oncology, 2015, 10, 123.	2.7	26
15	Musashi2 predicts poor prognosis and invasion in hepatocellular carcinoma by driving epithelial–mesenchymal transition. Journal of Cellular and Molecular Medicine, 2014, 18, 49-58.	3.6	79